The Cigna Group (The Cigna Group) Risk Assessment

View and export this data going back to 1982. Start your Free Trial

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of The Cigna Group is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison

For the Healthcare Plans subindustry, The Cigna Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Cigna Group Risk Assessment Distribution

For the Healthcare Plans industry and Healthcare sector, The Cigna Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where The Cigna Group's Risk Assessment falls into.

The Cigna Group (NYSE:CI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

The Cigna Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of The Cigna Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cigna Group (The Cigna Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » The Cigna Group (NYSE:CI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CI:Mexico CGN:Germany CGN:Germany C1IC34:Brazil CIGN:Austria

Address

900 Cottage Grove Road, Bloomfield, CT, USA, 06002

Website

https://www.cigna.com

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 18 million U.S. medical members covered as of the end of June 2023.

Executives

Cynthia Ryan	officer: EVP, CHRO	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Z, PHILADELPHIA PA 19192
Nicole S Jones	officer: EVP, General Counsel	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL18Y, PHILADELPHIA PA 19192
Agoglia Hoeltzel Mary T	officer: VP & Chief Accounting Officer	1601 CHESTNUT STREET, TWO LIBERTY PLACE, PHILADELPHIA PA 19192
Brian C Evanko	officer: President Government Business	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Y, PHILADELPHIA PA 19192
Everett Neville	officer: EVP, Strategy and Business Dev	ONE EXPRESS WAY, ST. LOUIS MO 63121
Paul A Sanford	officer: EVP Operations	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Z, PHILADELPHIA PA 19192
Phillip Ozuah	director	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Donna F Zarcone	director	C/O HARLEY DAVIDSON, 3700 W. JUNEAU AVE, MILWAUKEE WI 53208
Michael W Triplett	officer: President, US Markets	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Y, PHILADELPHIA PA 19192
Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
David Cordani	director, officer: President & CEO	THE CIGNA GROUP, 900 COTTAGE GROVE ROAD, BLOOMFIELD CT 06002
Jason D Sadler	officer: Pres., International Markets	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Y, PHILADELPHIA PA 19192
Eric P Palmer	officer: EVP, Chief Financial Officer	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL05Y, PHILADELPHIA PA 19192
David J Brailer	officer: EVP & Chief Health Officer	4 PRESIDIO TERRACE, SAN FRANCISCO CA 94118
Charles Berg	officer: Pres, Govt Programs & Sr Advsr	48 MONROE TURNPIKE, TRUMBULL CT 06611